📣 VC round data is live. Check it out!

BillionToOne Valuation Multiples

Discover revenue and EBITDA valuation multiples for BillionToOne and similar public comparables like Jiangsu Yuyue Medical, LivaNova, iRhythm Holdings, Merit Medical Systems and more.

BillionToOne Overview

About BillionToOne

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.


Founded

2016

HQ

United States

Employees

N/A

Financials (LTM)

Revenue: $363M
EBITDA: $56M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

BillionToOne Financials

BillionToOne reported last 12-month revenue of $363M and EBITDA of $56M.

In the same LTM period, BillionToOne generated $254M in gross profit, $56M in EBITDA, and $21M in net income.

Revenue (LTM)


BillionToOne P&L

In the most recent fiscal year, BillionToOne reported revenue of $305M and EBITDA of $37M.

BillionToOne is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 12%, and net margin of 2%.

See analyst estimates for BillionToOne
LTMLast FY202320242025202620272028
Revenue$363M$305M$72M$153M$305M
Gross Profit$254M$208M$17M$81M$208M
Gross Margin70%68%24%53%68%
EBITDA$56M$37M($73M)($27M)$20M
EBITDA Margin16%12%(102%)(18%)6%
EBIT Margin8%5%(97%)(31%)5%
Net Profit$21M$7M($83M)($42M)$7M
Net Margin6%2%(115%)(27%)2%

Financial data powered by Morningstar, Inc.

BillionToOne Stock Performance

BillionToOne has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


BillionToOne's stock price is $85.92.

BillionToOne share price increased by 14.3% in the last 30 days.

BillionToOne has an EPS (earnings per share) of $0.16.

See more trading valuation data for BillionToOne
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B-0.3%14.3%12.6%—$0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

BillionToOne Valuation Multiples

BillionToOne trades at 9.8x EV/Revenue multiple, and 63.0x EV/EBITDA.

See NTM and 2027E valuation multiples for BillionToOne

EV / Revenue (LTM)


BillionToOne Financial Valuation Multiples

As of May 23, 2026, BillionToOne has market cap of $4B and EV of $4B.

BillionToOne has a P/E ratio of 190.7x.

LTMLast FY202320242025202620272028
EV/Revenue9.8x11.7x49.6x23.3x11.7x
EV/EBITDA63.0x95.4x(48.8x)(129.6x)180.1x
EV/EBIT126.7x222.1x(51.2x)(75.5x)222.1x
EV/Gross Profit14.0x17.1x205.6x44.0x17.1x
P/E190.7xn/m(47.8x)(95.1x)n/m
EV/FCF151.2x227.1x(58.5x)(76.0x)227.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified BillionToOne Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

BillionToOne Margins & Growth Rates

BillionToOne grew revenue by 49% and EBITDA by 131% in the last fiscal year.

In the most recent fiscal year, BillionToOne reported gross margin of 68%, EBITDA margin of 12%, and net margin of 2%.

See estimated margins and future growth rates for BillionToOne

BillionToOne Margins

Last FY202420252026202720282029
Gross Margin68%53%68%71%
EBITDA Margin12%(18%)6%19%
EBIT Margin5%(31%)5%10%
Net Margin2%(27%)2%11%
FCF Margin5%(31%)5%9%

BillionToOne Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth49%113%100%49%
Gross Profit Growth55%368%158%55%
EBITDA Growth131%(62%)(172%)336%
EBIT Growth192%(32%)(134%)192%
Net Profit Growth549%(50%)(118%)549%
FCF Growth174%(23%)(133%)174%

Data powered by FactSet, Inc. and Morningstar, Inc.

BillionToOne Operational KPIs

BillionToOne's Rule of 40 is 68% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BillionToOne's Rule of X is 141% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for BillionToOne
LTMLast FY202320242025202620272028
Rule of 4054%68%———
Bessemer Rule of X111%141%———
S&M Expenses to Revenue32%33%——33%
G&A Expenses to Revenue15%14%——14%
R&D Expenses to Revenue16%16%31%24%16%
Opex to Revenue—63%121%84%63%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

BillionToOne Competitors

BillionToOne competitors include Jiangsu Yuyue Medical, LivaNova, iRhythm Holdings, Merit Medical Systems, Ottobock, Envista Holdings, Twist Bioscience, Rigaku, Medacta Group and Veracyte.

Most BillionToOne public comparables operate across Diagnostics & Genomics, Medical Devices, Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Jiangsu Yuyue Medical3.3x3.2x13.5x16.4x
LivaNova2.8x2.7x12.2x11.7x
iRhythm Holdings5.4x5.0x58.2x47.2x
Merit Medical Systems2.7x2.7x11.0x10.7x
Ottobock2.9x2.7x15.6x10.9x
Envista Holdings1.6x1.6x11.6x11.2x
Twist Bioscience9.8x8.8x(78.7x)(97.1x)
Rigaku6.5x6.3x28.0x26.5x

This data is available for Pro users. Sign up to see all BillionToOne competitors and their valuation data.

Start Free Trial

BillionToOne Funding History

Before going public, BillionToOne raised $391M in total equity funding, across 7 rounds.

Last private valuation of BillionToOne was $1B, after raising $130M in June 2024 from Adams Street Partners, Baillie Gifford, Civilization Ventures, and 6 other investors.


BillionToOne Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-24Series DAdams Street Partners; Baillie Gifford; Civilization Ventures; Eczacıbaşı Momentum; Fifty Years; Hummingbird Ventures; Libertus Capital; Neuberger Berman; Premji Invest$130M$1BBillionToOne is a next-generation molecular diagnostics company specializing in precision tests for prenatal screening and oncology, leveraging proprietary Quantitative Counting Templates (QCTs) technology to count DNA molecules with single base-pair precision. The company launched its first tests in 2020 and has served over 500,000 patients to date. Its flagship UNITY Fetal Risk Screen analyzes blood samples for cell-free DNA to assess risks of recessively inherited conditions like spinal muscular atrophy and cystic fibrosis, without needing amniocentesis or paternal samples. On June 21, 2024, BillionToOne raised $130 million in an oversubscribed, upsized Series D round led by Premji Invest, with participation from new investor Neuberger Berman and existing investors Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. The round valued the company at over $1 billion post-money, bringing total capital raised to nearly $400 million. Proceeds will expand and scale prenatal and oncology businesses, including liquid biopsy products. BillionToOne achieved $125 million in ARR within approximately four years, growing from $0M, demonstrating rapid traction in transforming the prenatal diagnostics segment. This follows a $125 million Series C in March 2022. Premji Invest's Akshay Rai joined the board, highlighting the platform's potential across medical specialties. Prior investors include NeoTribe Ventures, Norwest Venture Partners, Four Rivers Group, and Y Combinator.
Dec-22Series CAdams Street Partners; Baillie Gifford; Fifty Years; Hummingbird Ventures; Libertus Capital; Neotribe Ventures; Norwest; TIME BioVentures$49M$600MBillionToOne is a molecular diagnostics company focused on precision genomics for prenatal and oncology testing, offering products like the UNITY prenatal test that does not require paternal DNA samples. On December 15, 2022, it announced a $48.5 million Series C extension round from existing investors including Adams Street Partners, Baillie Gifford, Fifty Years, Hummingbird Ventures, Libertus Capital, Neotribe Ventures, Norwest, and TIME BioVentures, at an approximate post-money valuation of $600 million. This brought total funding to over $280 million since its first commercial product launch three years prior, combined with a $35 million upsized term loan from Bridge Bank to extend runway to end of 2024. The round followed a $125 million Series C in March 2022 and highlighted rapid growth, with test volumes and revenues more than doubling since then, though specific revenue figures were not disclosed. Funds were allocated to execute growth strategies for prenatal and oncology products, leveraging its Quantitative Counting Template technology. Investors cited the company's distinguished platform and scaling momentum as reasons for continued support. Post-round developments included a $130 million Series D in June 2024 at over $1 billion valuation led by Premji Invest and others, and a Nasdaq IPO in November 2025 raising $314 million at $2.7 billion valuation under ticker BLLN. Later revenue estimates showed $72 million in 2023 and $153 million in 2024, with prenatal testing driving profitability and 15% US market share, but no contemporaneous metrics for the 2022 round.
Mar-22Series CAdams Street Partners; Hummingbird Ventures$125M—BillionToOne is a next-generation molecular diagnostics company developing Quantitative Counting Templates (QCTs) technology for precise DNA molecule counting, enabling differentiated tests in prenatal screening and oncology, such as the UNITY Screen for genetic conditions like Down syndrome and cystic fibrosis using a single maternal blood sample. On March 30, 2022, it closed a $125 million Series C funding round co-led by new investor Adams Street Partners and existing investor Hummingbird Ventures, with participation from Baillie Gifford, NeoTribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital. The proceeds were allocated to expand commercial and clinical teams, scale laboratory capacity, support prenatal test growth, and conduct clinical studies for its liquid biopsy test in oncology. Thomas Bremner from Adams Street Partners joined the board, highlighting the company's execution in prenatal markets and potential in oncology.
Jun-21Series B500 Global; Fifty Years; Four Rivers Group; HOF Capital; Hummingbird Ventures; Libertus Capital; Neotribe Ventures; Norwest; Y Combinator$55M—BillionToOne is a precision diagnostics company based in Menlo Park, California, developing a patent-pending molecular counter platform designed to accurately count DNA molecules at the single-count level. The company aims to make molecular diagnostics more accurate, efficient, and accessible. In June 2021, BillionToOne closed a $55 million Series B funding round led by existing investor Hummingbird Ventures with participation from incoming investor Four Rivers Group, Neotribe Ventures, Norwest Ventures, and other backers including 500 Global, Fifty Years, HOF Capital, Libertus Capital, and Y Combinator. The company's revenue grew from $8.1 million in 2021 to $152.6 million in 2024, demonstrating strong commercial traction. By June 2025, the company achieved an annualized recurring revenue (ARR) of nearly $1.1 billion. In its most recent reported period (Q4 2025), BillionToOne reported total revenue of $96.1 million, with prenatal clinical testing revenue contributing $86.1 million.
Mar-20Series A500 Global; Abenteuer Ventures; Almoayed Ventures; Andrea Dusi; Civilization Ventures; Fifty Years; Friále; HOF Capital; Hummingbird Ventures; Libertus Capital; Neotribe Ventures; Pacific 8 Ventures$15M$149MBillionToOne, a precision diagnostics company, closed a follow-on Series A+ funding round of $15 million on March 10, 2020, led by Hummingbird Ventures and NeoTribe Ventures with participation from Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul, and HOF Capital. This round brought total funding to over $32.5 million. The funds supported commercial expansion of the UNITY prenatal test to all US states and R&D for future diagnostics including liquid biopsy products. The company planned to expand its CLIA-licensed lab capacity by over 20x and grow its commercial team to 50 account executives to meet demand from prenatal providers. Forge Global reports this as a Series B-2 round with $16.02MM raised at a post-money valuation of $148.58 million and $6.24 price per share. Hummingbird Ventures expressed confidence in BillionToOne's sequencing platform for cell-free DNA-based molecular testing amid surging demand for UNITY.
Mar-19Series A500 Global; Civilization Ventures; Fifty Years; HOF Capital; Hummingbird Ventures; Neotribe Ventures; Y Combinator$15M—BillionToOne closed a $15 million oversubscribed Series A funding round on March 13, 2019, co-led by Hummingbird Ventures and Neotribe Ventures, with participation from 500 Global, Civilization Ventures, Fifty Years, HOF Capital, and Y Combinator. The company, inventors of the patent-pending molecular counter platform, develops molecular diagnostics focused on prenatal testing.
Aug-17Seed500 Emerging Europe; Bryan Rosenblatt; David Chan; e2vc; Endpoint Ventures; Fifty Years; Friále; Luigi Bajetti; NewDo Venture; Pacific 8 Ventures; UpHonest Capital; Y Combinator$2M—BillionToOne, a precision diagnostics company co-founded by Oguzhan Atay and David Tsao, raised $2.4 million in a seed round in September 2017. The company had developed a proprietary molecular counter platform designed to quantify DNA molecules with single-base-pair precision for applications in prenatal screening and oncology diagnostics. At the time of this seed investment, BillionToOne was pre-revenue, preparing to launch its first product, UNITY, a noninvasive prenatal screening test for cystic fibrosis and spinal muscular atrophy. The company would go on to achieve significant growth, reaching $125 million in annual recurring revenue (ARR) by 2024 and raising $130 million in a Series D round that year at a valuation exceeding $1 billion.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About BillionToOne

When was BillionToOne founded?BillionToOne was founded in 2016.
Where is BillionToOne headquartered?BillionToOne is headquartered in United States.
Is BillionToOne publicly listed?Yes, BillionToOne is a public company listed on Nasdaq.
What is the stock symbol of BillionToOne?BillionToOne trades under BLLN ticker.
When did BillionToOne go public?BillionToOne went public in 2025.
Who are competitors of BillionToOne?BillionToOne main competitors include Jiangsu Yuyue Medical, LivaNova, iRhythm Holdings, Merit Medical Systems, Ottobock, Envista Holdings, Twist Bioscience, Rigaku, Medacta Group, Veracyte.
What is the current market cap of BillionToOne?BillionToOne's current market cap is $4B.
What is the current revenue of BillionToOne?BillionToOne's last 12 months revenue is $363M.
What is the current revenue growth of BillionToOne?BillionToOne revenue growth (NTM/LTM) is 38%.
What is the current EV/Revenue multiple of BillionToOne?Current revenue multiple of BillionToOne is 9.8x.
Is BillionToOne profitable?Yes, BillionToOne is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of BillionToOne?BillionToOne's last 12 months EBITDA is $56M.
What is BillionToOne's EBITDA margin?BillionToOne's last 12 months EBITDA margin is 16%.
What is the current EV/EBITDA multiple of BillionToOne?Current EBITDA multiple of BillionToOne is 63.0x.
What is the current FCF of BillionToOne?BillionToOne's last 12 months FCF is $24M.
What is BillionToOne's FCF margin?BillionToOne's last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of BillionToOne?Current FCF multiple of BillionToOne is 151.2x.
How many companies BillionToOne has acquired to date?BillionToOne hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies BillionToOne has invested to date?BillionToOne hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to BillionToOne

Lists including BillionToOne

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial